Humanin shows emerging therapeutic promise for cytoprotection in Acute Respiratory Distress Syndrome

Acute Respiratory Distress Syndrome (ARDS) is a severe inflammatory lung condition characterized by diffuse alveolar damage, hypoxemia, and high mortality. Current treatments are largely supportive, failing to directly address the underlying cellular injury and mitochondrial dysfunction that drive disease progression. Mitochondrial dysfunction is a key pathological feature in ARDS, contributing to oxidative stress, inflammation, and apoptosis. Mitochondrial-derived peptides (MDPs) like Humanin offer a novel therapeutic avenue by enhancing cellular resilience and cytoprotection.

This review systematically synthesizes current literature on the role of mitochondrial-derived peptides (MDPs), specifically Humanin, in the context of Acute Respiratory Distress Syndrome (ARDS). It examines preclinical and mechanistic studies exploring Humanin's cytoprotective effects, its influence on mitochondrial function, and its anti-inflammatory properties. The authors analyzed various in vitro and in vivo models of lung injury to identify common therapeutic mechanisms and evaluate Humanin's potential as a novel intervention.

The review highlights that Humanin consistently exhibits potent cytoprotective effects across various models of lung injury relevant to ARDS. It modulates critical cellular pathways, including the inhibition of apoptosis and reduction of oxidative stress, thereby preserving mitochondrial integrity and function. Humanin has been shown to interact with specific cell surface receptors, activating downstream signaling cascades such as STAT3 and ERK1/2, which promote cell survival and anti-inflammatory responses. Furthermore, it directly counteracts pro-apoptotic signals induced by inflammatory mediators, leading to improved cellular viability.

Humanin significantly mitigates cellular damage and dysfunction in lung epithelial and endothelial cells exposed to ARDS-mimicking conditions, suggesting a broad protective capacity. The peptide's ability to enhance cellular resilience against diverse stressors, including hypoxia, inflammation, and oxidative damage, positions it as a promising candidate for mitigating the multi-faceted pathology of ARDS. Its pleiotropic actions on mitochondrial health and inflammatory pathways underscore its therapeutic potential.